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Background. MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine 
licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this 
study, we assessed the immunogenicity and safety of another MMR vaccine (MMR-RIT [Priorix, GlaxoSmithKline]) compared 
with those of the MMR II in 12- to 15-month-old children who received it as a first dose.
Methods. In this phase III, observer-blinded, noninferiority, lot-to-lot consistency clinical trial (ClinicalTrials.gov identifier 
NCT01702428), 5003 healthy children were randomly assigned to receive 1 dose of MMR-RIT (1 of 3 production lots) or MMR 
II along with other age-recommended routine vaccines. We evaluated the immunogenicity of all vaccines in terms of antibody 
concentrations (by using an enzyme-linked immunosorbent assay or electrochemiluminescence assay) and/or seroresponse rates 
43 days after vaccination. We also assessed the reactogenicity and safety of the vaccines.
Results. Immunoresponses after vaccination with MMR-RIT were robust and noninferior to those after vaccination with the 
MMR II. Immunogenicity of the 3 production lots of MMR-RIT was consistent; more than 97% of the children had a seroresponse 
to MMR components. The coadministered vaccines elicited similar immunoresponses in the MMR-RIT and MMR II groups. Both 
MMR vaccines resulted in comparable reactogenicity profiles, and no safety concerns were detected.
Conclusions. If licensed, the MMR-RIT could provide a valid option for the prevention of measles, mumps, and rubella in 
children in the United States and would reduce potential risks of a vaccine shortage.
Keywords. immunogenicity; measles-mumps-rubella vaccine; safety.
The only combined measles, mumps, and rubella (MMR) vac-
cine currently available for use in the United States is the MMR 
II (M-M-R II, Merck & Co, Inc.) [1]. Routine 2-dose MMR II 
vaccination has led to the successful elimination of endemic 
measles and rubella and a decrease in the number of mumps 
cases by >99% compared with those in the prevaccine era [2–
4]. However, these diseases are still present in the population, 
as revealed by the increasing number of measles and mumps 
outbreaks in recent years [4, 5]. Having another licensed MMR 
vaccine available in the United States would decrease the public 
health risk associated with potential interruptions in the MMR 
II vaccine supply.
The MMR-RIT (Priorix, GlaxoSmithKline [GSK]) is a com-
bined MMR vaccine first licensed in the 1990s outside the 
United States and is currently available in more than 100 coun-
tries, where it has an indication and recommended schedules 
similar to those of the MMR II [6]. Regulatory requirements in 
the United States are now different than those when MMR-RIT 
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was licensed originally, and a full development program to sup-
port US licensure of MMR-RIT is underway.
As part of that program, we conducted a phase III study to 
evaluate the immunogenicity and safety of the MMR-RIT com-
pared with those of the MMR II when it is given as a first dose 
to 12- to 15-month-old children. This study was also aimed to 
assess the consistency of 3 production lots of MMR-RIT and 
evaluate the immunoresponses to vaccines routinely coadmin-
istered according to the US schedule.
METHODS
Study Design and Participants
This study was a phase IIIa, observer-blinded, random-
ized, controlled, noninferiority, lot-to-lot consistency study 
(ClinicalTrials.gov NCT01702428) conducted between 
November 2012 and April 2015 at 92 centers in Estonia, 
Finland, Mexico, Spain, and the United States.
We randomly assigned children aged 12 to 15  months in 
a 3:1 ratio to receive 1 dose of either 1 of 3 production lots 
of MMR-RIT or 1 of 2 commercial lots of the control MMR 
II (Supplementary Figure 1). All children concomitantly 
received a first dose of hepatitis A  vaccine (HAV [Havrix, 
GSK]) and varicella vaccine (VV [Varivax, GSK]), and chil-
dren in the United States also received a fourth dose of the 
13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 
13, Pfizer, Inc.]). The study consisted of in-person visits on 
day 0 (D0) and D42 and a telephone call on D180. We admin-
istered vaccines on D0 and collected blood samples (5 mL per 
child and visit) to assess antibody responses on D0 and D42.
We conducted the study in accordance with the Declaration 
of Helsinki and International Conference on Harmonisation 
Good Clinical Practice guidelines. The study protocol was 
reviewed and approved by independent ethics review com-
mittees or institutional review boards as applicable. Parents or 
legally acceptable representatives provided written informed 
consent for the children before enrollment.
Children aged 12 to 15 months in stable health were eligi-
ble. We excluded children with a history of, known exposure 
to, or previous vaccination against measles, mumps, rubella, 
varicella, herpes zoster, and/or hepatitis A disease, a history of 
allergic disease or reactions, or acute disease (See "Other eli-
gibility criteria" in the Supplementary Methods section of the 
Supplementary Material).
Randomization and Blinding
We stratified the randomization algorithm according to coun-
try, and we used a minimization procedure to ensure the 
correct balance of treatment groups within each center. We 
performed the treatment allocation at each center using a cen-
tral randomization system on the Internet.
The study was double blinded for the MMR-RIT lot-to-lot 
consistency evaluation and observer blinded for the compari-
son between the MMR-RIT and MMR II. Because of the poten-
tial color differences between reconstituted MMR-RIT and 
MMR II, the staff handling these vaccines were not involved in 
the assessment of study end points.
Study Vaccines
The composition of the MMR vaccines used is shown in 
Supplementary Table 1. The formulations of HAV, VV, and 
PCV13 have been described previously [7–9]. The MMR vac-
cines were injected subcutaneously in the left triceps; VV, 
subcutaneously in the right triceps; HAV, intramuscularly in 
the right anterolateral thigh; and PCV13 (only to children in 
the United States), intramuscularly in the left anterolateral 
thigh.
Immunogenicity Assessments
We measured immunoglobulin G (IgG) antibodies to mea-
sles, mumps, rubella, hepatitis A  virus, and varicella-zos-
ter virus (VZV) by using commercial enzyme-linked 
immunosorbent assay kits (See "Immunogenicity assessments" 
in the Supplementary Methods section of the Supplementary 
Material). We quantified IgG antibodies against Streptococcus 
pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 
19F, and 23F using an in-house electrochemiluminescence assay 
(GSK, Wavre, Belgium, validation data, unpublished data).
We defined seroresponse as D42 antibody concentra-
tions ≥200 mIU/mL for anti-measles, ≥10 enzyme-linked 
immunosorbent assay units (EU)/mL for anti-mumps (as 
used in previous studies [10]), ≥10 IU/mL for anti-rubella, 
and ≥75 mIU/mL for anti-VZV in children who were sero-
negative on D0 (See "Immunogenicity assessments" in the 
Supplementary Methods section of the Supplementary 
Material for the seronegativity thresholds). Seroresponse 
to hepatitis A  virus was defined as a D42 anti-hepatitis 
A  virus antibody concentration ≥15 mIU/mL in children 
with an antibody concentration <15 mIU/mL on D0 or, 
otherwise, a ≥2-fold increase in antibody concentration on 
D42. To define seroresponses, we used antibody concentra-
tion thresholds for anti-mumps and anti-rubella antibodies 
that were accepted by the Food and Drug Administration 
(FDA) as end points that define a clinically meaningful 
change in antibody titer; for anti-VZV antibodies, the sero-
response threshold was accepted by the FDA as a threshold 
commonly used in previous studies [11]. The seroresponse 
threshold for measles was based on comparison with titers 
from World Health Organization International Reference 
II and III. In the context of a head-to-head vaccine trial 
designed to demonstrate noninferiority, the FDA consid-
ered these thresholds acceptable immunoresponse levels.
D
ow
nloaded from
 https://academ
ic.oup.com
/jpids/advance-article-abstract/doi/10.1093/jpids/piz010/5372494 by Tam
pere U
niversity and U
niversity H
ospital user on 30 O
ctober 2019
Immunogenicity and Safety of MMR Vaccine • JPIDS 2019:XX (XX XXXX) • 3
Reactogenicity and Safety Assessments
We recorded the solicited local adverse events (AEs) of pain, 
redness, and swelling at the MMR injection site from D0 to 
D3 (Supplementary Figure 1). We assessed the solicited general 
AEs of drowsiness, loss of appetite, and irritability/fussiness 
from D0 to D14 and assessed fever (temperature, ≥38.0°C), 
rash, parotid/salivary gland swelling, and febrile convulsions 
or signs of meningeal irritation from D0 to D42.
We documented unsolicited AEs from D0 to D42 and AEs that 
prompted an emergency department visit, serious AEs (SAEs), 
and new-onset chronic disease (NOCD) (Supplementary 
Table 6) during the entire study period (D0–D180).
We graded the intensity of all solicited AEs from 0 to 3 (See 
Supplementary Figure 2 footnote for definitions of grade 3 
AEs). We considered all solicited local AEs as causally related 
to vaccination, and the investigator assessed the causality of 
other AEs.
Statistical Analyses
We planned to enroll 5000 children to ensure randomization of 
1250 children to each MMR-RIT lot group and 625 children to 
each MMR II lot group. Assuming a 20% nonevaluable rate in 
the according-to-protocol (ATP) cohort for immunogenicity, 
we estimated that 4000 children (1000 in each MMR-RIT lot 
group and 500 in each MMR II lot group) would be evaluable. 
Data for the 2 MMR II lots were pooled for all analyses.
The study had 5 primary objectives. The first and second 
primary objectives were to demonstrate the consistency of 3 
lots of MMR-RIT in terms of seroresponse rates (SRRs) (objec-
tive 1) and adjusted antibody geometric mean concentrations 
(GMCs) (objective 2) for measles, mumps, and rubella on D42 
(success criteria, the 95% confidence interval [CI] for the lot 
difference in SRR was within the [−5%; 5%] pre-specified mar-
gin and the 95% CI for the GMC lot ratio was within the [0.67; 
1.5] pre-specified margin for all 3 antigens). The third and 
fourth primary objectives were to demonstrate noninferiority 
of the MMR-RIT (pooled lots) over the MMR II in terms of 
SRRs (objective 3) and antibody GMCs (objective 4) for mea-
sles, mumps, and rubella on D42 (success criteria, the lower 
limit [LL] of the 95% CI for the group difference in SRRs 
[pooled MMR-RIT − MMR II] was −5% or higher and the LL 
of the 95% CI for the adjusted GMC ratio [pooled MMR-RIT/
MMR II] was ≥0.67 for all 3 antigens). The fifth primary objec-
tive was to demonstrate an acceptable immunoresponse to the 
MMR-RIT in terms of the SRR to measles, mumps, and rubella 
on D42 (success criterion, the LL of the 95% CI for the SRR in 
the pooled MMR-RIT group was ≥90% for all 3 antigens).
The secondary objectives of this study included assessment 
of the immunogenicity of the coadministered vaccines HAV, 
VV, and PCV13 in terms of SRRs and/or GMCs and assess-
ment of the safety and reactogenicity of the MMR-RIT and 
MMR II (Supplementary Tables 3–6 and Figure 2). All the 
immunogenicity objectives were statistically powered except 
for the assessment of HAV immunogenicity in terms of SRRs.
All MMR immunogenicity analyses were conducted on the 
ATP cohort for immunogenicity, which included children for 
whom prevaccination and postvaccination serology results for 
at least 1 of the MMR antigens were available, who had a prevac-
cination concentration below the assay cutoff for at least 1 of the 
MMR antigens, who did not meet any elimination criteria up 
to D42, and who complied with protocol-defined procedures. 
We tested immunogenicity of the coadministered vaccines in 
subsets of children in the ATP cohort for immunogenicity (See 
"Statistical analyses" in the Supplementary Methods section of 
the Supplementary Material).
For each of the 3 separate MMR-RIT lots, for the pooled 
MMR-RIT lots, and for the MMR II group, we summarized the 
antibody GMCs for anti-measles, anti-mumps, and anti-rubella 
on D42 with their 95% CIs and the SRRs (defined as the percent-
age of children who had a seroresponse to these antibodies on 
D42) with their exact 95% CIs. We then tabulated, for each anti-
gen, the difference in SRRs between groups (pooled MMR-RIT 
− MMR II) with their standardized asymptotic 95% CIs and the 
adjusted GMC ratios between groups (pooled MMR-RIT/MMR 
II) with their 95% CIs. To assess consistency across the 3 MMR-
RIT lots, we computed the differences in SRRs (eg, MMR-RIT lot 
1 − MMR-RIT lot 2) with their standardized asymptotic 95% CIs.
To assess the immunoresponses of the coadministered vac-
cines, we tabulated the GMCs for antibodies against VZV, hep-
atitis A virus, and S pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 
9V, 14, 18C, 19A, 19F, and 23F on D42 with their 95% CIs. We 
computed the SRRs to VZV and hepatitis A virus on D42 with 
their exact 95% CIs. To test the prespecified noninferiority cri-
teria, we calculated the adjusted GMC ratios between groups 
(pooled MMR-RIT/MMR II) with their 95% CIs for all the 
coadministered vaccines and the difference in SRRs between 
groups (pooled MMR-RIT − MMR II), with their asymptotic 
standardized 95% CIs for anti-VZV.
The safety and reactogenicity analyses were conducted on 
the total vaccinated cohort, which included all children with 
≥1 documented administration of either MMR-RIT or MMR 
II. We tabulated the number and percentage of children (with 
exact 95% CIs) reporting each of the safety and reactogenicity 
variables assessed.
Statistical analyses were performed using SAS 9.3 (SAS, 
Inc, Cary, North Carolina) on SAS Drug Development 4.3 (See 
"Statistical analyses" in the Supplementary Methods section of 
the Supplementary Material).
RESULTS
Study Participants and Demographic Characteristics
We enrolled 5016 children, 5003 of whom were randomly 
assigned and received a single dose of MMR-RIT lot 1 
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(n = 1239), lot 2 (n = 1232), or lot 3 (n = 1243) or MMR II 
(n  =  1289) (Figure 1). A  total of 4759 children completed 
the study; the main reasons for discontinuation were loss to 
follow-up and consent of withdrawal not because of an AE. 
Overall, demographic characteristics were similar between the 
MMR-RIT and MMR II recipients (Table 1).
Immunogenicity Assessments
Noninferiority of the Immunoresponse to MMR-RIT Versus MMR II
On D42, the SRRs of the MMR-RIT group (pooled lots) were 
98.2% for anti-measles, 98.4% for anti-mumps, and 97.3% for 
anti-rubella antibodies (Table 2). The SRRs to the MMR com-
ponents observed after MMR-RIT vaccination were considered 
acceptable immunoresponses and were noninferior to SRRs in 
the MMR II group (criteria met; see “Statistical Analyses” for 
details) (Table 2).
The antibody GMCs to the MMR components were similar 
between MMR-RIT and MMR II groups (Table 2). MMR-RIT 
vaccination was noninferior to MMR II in terms of GMCs for 
anti-measles, anti-mumps, and anti-rubella antibodies (crite-
rion met; see Statistical analyses for details).
Lot-to-Lot Consistency of MMR-RIT
Children in the 3 MMR-RIT lot groups had high SRRs; anti-
bodies against measles ranged from 97.8% to 98.6%, against 
mumps from 98.0% to 98.6%, and against rubella from 97.1% 
to 97.7%. The 3 lots were consistent in terms of SRRs and 
GMCs to all MMR components and met prespecified criteria 
(Supplementary Table 2).
Immunoresponses to the Coadministered Vaccines
We evaluated the immunogenicity of VV in 2120 children 
enrolled in the United States (VZV subset). In addition, we also 
analyzed the immunogenicity of HAV in 1081 of these 2120 
children (HAV subset) and the immunogenicity of PCV13 in 
the remaining 1039 children (PCV13 subset).
On D42, ≥90.2% of the children had a seroresponse against 
the VV (Supplementary Table 3). The SRR to VV in the MMR-
RIT group was noninferior to that in the MMR II group. Anti-
VZV antibody concentrations were also similar between study 
groups, and anti-VZV GMCs, comparing the MMR-RIT and 
MMR II groups, were noninferior (Supplementary Table 3).
Table 1. Demographic Characteristics of the Study Participants (Total 
Vaccinated Cohort)
Characteristic
MMR-RIT Group 
(n = 3714)
MMR II Group  
(n = 1289)
Age at dose 1 (mean [SD]) (months) 12.3 (0.7) 12.3 (0.7)
Sex (n [%])a   
 Female 1816 (48.9) 618 (47.9)
Geographic ancestry (n [%])   
 White-Caucasian/European heritage 2814 (75.8) 970 (75.3)
 African heritage/African American 169 (4.6) 70 (5.4)
 Asian heritage 127 (3.4) 46 (3.6)
 American Indian or Alaskan native 95 (2.6) 31 (2.4)
 Other 509 (13.7) 172 (13.3)
Abbreviation: SD, standard deviation.
aPercentages shown are of children in the category.
Figure 1. Flow diagram of the study participants. Abbreviations: ATP, according-to-protocol; N, number of children; n, number of children within the category.
D
ow
nloaded from
 https://academ
ic.oup.com
/jpids/advance-article-abstract/doi/10.1093/jpids/piz010/5372494 by Tam
pere U
niversity and U
niversity H
ospital user on 30 O
ctober 2019
Immunogenicity and Safety of MMR Vaccine • JPIDS 2019:XX (XX XXXX) • 5
SRRs to HAV were 88.8% in the MMR-RIT group and 
87.1% in the MMR II group (Supplementary Table 3). GMCs 
of anti-hepatitis A virus antibodies were similar between study 
groups, and antibody concentrations in the MMR-RIT group 
were noninferior to those in the MMR II group (Supplementary 
Table 3).
The antibody concentrations to the components of PCV13 
were comparable between study groups, and GMCs in the 
MMR-RIT group were noninferior to those in the MMR II 
group (Supplementary Table 4).
Reactogenicity and Safety
The frequencies of reported solicited local and general AEs 
were similar in children in the pooled MMR-RIT and MMR 
II groups. The most frequently reported solicited local AE 
in both groups was injection site pain (25.9% in the MMR-
RIT group, 28.1% in the MMR II group), followed by redness 
(24.5% in the MMR-RIT group, 25.2% in the MMR II group) 
(Supplementary Figure 2). Irritability/fussiness was the most 
frequently reported solicited general AE (63.3% in the MMR-
RIT group, 65.9% in the MMR II group) (Supplementary 
Figure 2).
Reported fevers peaked during D5 to D12 (Figure 2) and 
were comparable between groups (19.7% in the MMR-RIT 
group, 18.2% in the MMR II group) (Supplementary Figure 
2); ≤13.9% of the children had a fever considered causally 
related to vaccination, and ≤1.4% of the children had a grade 
3 fever. The incidence of fever during D0 to D42 was 34.7% in 
the MMR-RIT group and 33.1% in the MMR II group; fever 
was considered causally related to vaccination in ≤18.9% of the 
children, and ≤2.9% of the children had a grade 3 fever. The 
daily prevalence and height of fever over the 43 days after vac-
cination were similar across the 3 groups of individual MMR-
RIT lots and in the MMR II group (Figure 2).
Localized or generalized rashes were reported at the same 
frequency in both study groups (Supplementary Table 5). 
Measles/rubella-like rash occurred in ≤6.6% of the children, 
and varicella-like rash occurred in ≤7% of the children. From 
Table 2. Noninferiority of MMR-RIT (Pooled Lots) Over MMR II in Terms 
of Anti-Measles, Anti-Mumps, and Anti-Rubella SRRs and Adjusted GMCs 
and Acceptable Immunoresponse of MMR-RIT (Pooled Lots) on Day 42 
(According-to-Protocol Cohort for Immunogenicity)a
Parameter MMR-RITb MMR II
Difference in SRRs (Pooled 
MMR-RIT SRR − MMR II 
SRR)c or Adjusted GMC 
Ratio (Pooled MMR-RIT 
GMC/MMR II GMC)d
SRR (% [95% CI]) 
 Anti-measles 98.2 (97.6 to 98.6) 98.0 (97.0 to 98.7) 0.18 (−0.68 to 1.25)
 Anti-mumps 98.4 (97.9 to 98.8) 97.6 (96.5 to 98.4) 0.81 (−0.10 to 1.96)
 Anti-rubella 97.3 (96.7 to 97.9) 98.5 (97.6 to 99.1) −1.15 (−2.00 to −0.15)
Adjusted GMCs 
(95% CI)
   
 Anti-measles 3165.2 3215.4 0.98 (0.93 to 1.05)
 Anti-mumps 76.4 73.0 1.05 (0.99 to 1.11)
 Anti-rubella 52.5 60.0 0.87 (0.83 to 0.92)
Abbreviations: CI, confidence interval; SRR, seroresponse rate (defined as the percentage of initially seronega-
tive participants with a concentration above seroresponse)
aThe adjusted GMC is the geometric mean antibody concentration from an analysis of variance model on 
log-transformed concentrations with treatment group and country as factors; the threshold for each antibody 
was 200 mIU/mL for anti-measles, 10 EU/mL for anti-mumps, and 10 IU/mL for anti-rubella. The numbers of 
participants for whom both prevaccination and postvaccination results were available were 3248 (MMR-RIT) 
and 1137 (MMR II) for anti-measles, 3187 (MMR-RIT) and 1107 (MMR II) for anti-mumps, and 3245 (MMR-RIT) 
and 1135 (MMR II) for anti-rubella.
bAcceptable immunoresponse to MMR-RIT was demonstrated if the lower limit of the 95% CI for the SSR in 
the MMR-RIT group (pooled lots) was ≥90% for anti-measles, anti-mumps, and anti-rubella.
cStandardized asymptotic 95% CI.
dThe 95% CI for the adjusted GMC ratio (analysis of variance model: adjustment for country—pooled variance 
with >2 groups). Values in bold indicate that noninferiority criteria were met: the lower limit of the 95% CI for 
the difference in SRRs (pooled MMR-RIT − MMR II) was −5% or higher, and the lower limit of the 95% CI for 
the adjusted GMC ratio (pooled MMR-RIT/MMR II) was ≥0.67.
Figure 2. Prevalence of fever from day 0 to day 42 after vaccination (total vaccinated cohort). For visualization purposes, the scale of the y axis is different in 
each graph.
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D0 to D42, 10 (0.3%) children from the MMR-RIT group 
and 3 (0.2%) children from the MMR II group had docu-
mented febrile convulsions or signs of meningeal irritation 
(Supplementary Table 5); 4 cases of febrile convulsions or signs 
of meningeal irritation in the MMR-RIT group and 2 in the 
MMR II group occurred during the D5 to D12 postvaccina-
tion period and were considered vaccination related. Medical 
advice was sought in 10 cases of febrile convulsions/signs of 
meningeal irritation. We did not record any episodes of parotid 
or salivary gland swelling in this study.
We found similar incidences of unsolicited AEs, SAEs, AEs 
that prompted an emergency department visit, and NOCDs 
between the MMR-RIT and MMR II groups (Supplementary 
Table 6). Grade 3 unsolicited AEs were reported in ≤6.6% of 
the children, and SAEs in ≤2.1%. NOCDs were documented 
in 3.4% of MMR-RIT recipients and in 3.7% of MMR II recip-
ients; the most common NOCDs were atopic dermatitis (0.7% 
in the MMR-RIT group, 0.5% in the MMR II group) and 
eczema (0.4% in the MMR-RIT group, 0.8% in the MMR II 
group). No deaths occurred in this study.
DISCUSSION
In this study, we found that vaccination with MMR-RIT induced 
robust immunoresponses that were noninferior to immuno-
responses after MMR II vaccination in 12- to 15-month-old 
children. More than 97% of the children had a seroresponse 
against the 3 MMR-RIT components. We also found that the 3 
lots of MMR-RIT were consistent in terms of SRRs and GMCs. 
Although the point estimates for the responses to the rubella 
component of MMR-RIT were slightly lower than those of the 
MMR II, the lower limit of the 95% CI was above the prespec-
ified level, the GMC for rubella antibodies was fivefold higher 
than the threshold of 10 IU/mL, and the MMR-RIT rubella 
response met statistical noninferiority to MMR II. In addition, 
we found that the immunoresponses to the coadministered 
vaccines (VV, HAV, and PCV13) were similar between the two 
MMR vaccine groups (MMR-RIT and MMR II). Overall, these 
results show that the MMR-RIT met the prespecified criteria 
for noninferiority to the MMR II.
Our immunogenicity results are similar to those from pre-
vious first-dose studies of this vaccine with regard to serore-
sponses to the 3 MMR components [12, 13] and with SRRs and 
GMCs [14, 15].
The reactogenicity profiles of the 2 MMR vaccines were 
comparable, and we did not detect any new safety concerns. 
The peak in fever between D5 and D12 after vaccination was 
consistent with that in many previous reports [13, 16–19], and 
it has been attributed to the replication of the measles compo-
nent of the MMR vaccines. The strains of measles virus in the 
MMR-RIT and MMR II are different; the MMR-RIT contains 
the Schwarz strain, and the MMR II contains the Edmonston-
Enders (Moraten) strain. However, these strains are identi-
cal at the nucleotide level [20, 21], which is in line with the 
Figure 3. Focus on the patient. Summary contextualizing the outcomes of the study for the convenience of health care professionals.
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similar fever profiles observed in both of our vaccine groups. 
The mumps virus strain in the MMR-RIT is RIT 4385, derived 
from the Jeryl Lynn B strain used in the MMR II vaccine. The 
Jeryl Lynn component 1 is identical in both mumps strains at 
the protein level; only 1 silent mutation at the nucleotide level 
exists [22]. Accordingly, the reactogenicity profiles of both 
mumps strains are comparable, as shown in this and previous 
studies [23–25]. In addition, the MMR-RIT and MMR II con-
tain the same rubella stain (Wistar RA27/3).
In this study, we found that approximatively 13% of the 
children experienced a rash related to vaccination, which was 
slightly higher than the incidence reported in other studies of 
MMR vaccines [13, 24, 25]. In this trial, parents and legally 
accepted representatives were instructed exhaustively on 
detecting and reporting different rash types, which could have 
prompted increased reporting. However, rashes related to vac-
cination were reported at similar rates for both vaccine groups.
A limitation of this study was that our results cannot be gen-
eralized to children who did not comply with the inclusion cri-
teria but who would still be vaccinated in the clinical practice 
(eg, children with past exposure to 1 of the 3 viruses contained 
in the MMR vaccine).
In conclusion, results of this study show that immunore-
sponses after a first dose of MMR-RIT were noninferior to those 
of the US-registered vaccine MMR II. These results suggest 
that MMR-RIT could be a valid option for preventing measles, 
mumps, and rubella in children in the United States and help-
ing to ensure that the United States has a second MMR vaccine 
available in the event of a hypothetical MMR vaccine shortage.
For the convenience of health care professionals, a sum-
mary contextualizing the outcomes of this study is displayed 
in Figure 3.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious 
Diseases Society online.
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